UPDATED: Verastem shares crater on Twitter chatter around cancer data

John Carroll Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response ...

Will docs jump on new biosims? Survey shows they’ll need some nudging

Carly Helfand Drugmakers are well aware of the biosimilars threatening to steal sales and market share from some of the world's best-selling biologics. Doctors, though? Not so much, ...

Shire might dial up its $30B Baxalta offer, but not without more info

Alok Saboo Shire may consider upping its pitch for Baxalta, but first it needs more details on the financial future of its target. FierceBiotech News

Amarin wins injunction against FDA in free speech case

Eric Palmer On Friday, Amarin won what was being called a First Amendment free speech victory for drugmakers. It got a federal court to say the FDA cannot bar Amarin from discussing ...

Perrigo CEO: Think Mylan’s buyout will come easily? Think again

Carly Helfand Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan's generics business for $ 40.5 billion. Mylan's ...

UPDATED: Sanofi and Regeneron pick up a blockbuster cardio approval–with a catch

Damian Garde Sanofi and Regeneron won an expected FDA approval for the first of a new class of cholesterol drugs expected to alter the landscape in cardiology, but regulators stopped ...

Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes

Damian Garde A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of migraine therapy, racing to capitalize on what analysts ...

‘Modern Family’ star signs on with BMS for immuno-oncology awareness

Carly Helfand Pharma-watchers may be very familiar with immuno-oncology. But the average American doesn't necessarily know what the term means–or why it's important. Bring ...

Playing catch-up on Big Biotech goal, Shire broadens M&A focus

Carly Helfand Shire's $ 54 billion tie-up with AbbVie–and the subsequent cancellation of that deal–shook up employees and stalled CEO Flemming Ornskov's plans to ...

Takeda chairman Hasegawa out as JPMA vice president

Alok Saboo FierceBiotech News

Gilead takes a $125M FDA shortcut with its latest HIV combo

Damian Garde Last year, Gilead Sciences paid $ 125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment ...

Does brand + generic really add up? Sandoz, Actavis execs count the ways

Carly Helfand These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, ...
Page 4 of 50« First...23456...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS